JP
Therapeutic Areas
uniQure Pipeline
| Drug | Indication | Phase |
|---|---|---|
| AMT-130 | Huntington's Disease | Phase 1/2 |
| AMT-162 | Amyotrophic Lateral Sclerosis (ALS) | Preclinical |
| AMT-260 | Temporal Lobe Epilepsy / Mesial Temporal Lobe Epilepsy | Preclinical |
| Undisclosed Program | Alzheimer's Disease | Preclinical |
| Etranacogene Dezaparvovec (AMT-061) | Hemophilia B | Approved |
Leadership Team at uniQure
MK
Matt Kapusta
Chief Executive Officer
WA
Walid Abi-Saab, M.D.
Chief Medical Officer
AA
Amin Abujoub, Ph.D.
Chief Technical Operations Officer
EB
Erin Boyer
Chief People and Culture Officer
CK
Christian Klemt
Chief Financial Officer
KO
Kylie O’Keefe
Chief Customer and Strategy Officer
RP
Richard Porter, Ph.D.
Chief Business and Scientific Officer
DM
David Meek
Non-Executive Member (Chairman of the Board)